Lucas Bondurant

Lucas BonDurant is a Principal Scientist at Alnylam Pharmaceuticals since April 2018, where significant contributions include leading the identification of siRNA-based development candidates for metabolic disease programs and mentoring junior scientists. Prior experience includes roles as Senior Scientist and Scientist, along with an undergraduate researcher position at Missouri State University. Lucas BonDurant holds a Ph.D. in Molecular Medicine from the University of Iowa and a Bachelor's Degree in Cell and Molecular Biology from Missouri State University. Additional educational pursuits include studies at La Universidad de Salamanca. Skills encompass extensive knowledge in metabolic characterization of animal models and various molecular biology techniques.